An open-label, multicenter, phase II study of AT-101 in combination with rituximab in patients with untreated, grade I-II, follicular non-Hodgkin's lymphoma.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2010
At a glance
- Drugs AT 101; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Ascenta Therapeutics
- 04 Dec 2008 Planned end date changed from 1 Aug 2008 to 1 Nov 2008, according to ClinicalTrials.gov.
- 04 Dec 2008 Status changed from active, no longer recruiting to completed,according to ClinicalTrials.gov.
- 03 May 2008 Status changed from recruiting to in progress.